Omega-3 Fatty Acids Increase Weight and Quality of Life Scores in Patients With Advanced Non-Small Cell Lung Cancer and Cancer Cachexia: A Meta-Analysis

Overview

Journal Integr Cancer Ther

Publisher Sage Publications

Specialties Oncology
Pharmacology

Date 2024 Aug 29

PMID 39199013

Authors

Alfredo V Chua Jr

Aylmer Rex B Hernandez

Marvin Jonne L Mendoza

Michael D San Juan

Affiliations

Soon will be listed here.

Abstract

Background: Cancer cachexia is a common debilitating weight loss syndrome in advanced cancer, particularly lung cancer. Omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, with their immune-modulating effects, have been used to improve the nutritional status of patients with cancer cachexia.

Aim: Evaluate the effects of omega-3 fatty acids in change in weight and lean body/skeletal mass, and health-related quality of life scores (HRQoL) in patients with advanced non-small cell lung cancer and cancer cachexia.

Design And Data Sources: Clinical trials from electronic databases and unpublished literature (date of last search 20 December 2023) were independently reviewed and evaluated by authors for their methodological quality. Data from eligible trials were extracted and analyzed in a meta-analysis.

Results: Six trials were included. Five trials (354 patients) assessed change in weight; 2 trials (132 patients) assessed change in lean body/skeletal mass and HRQoL scores (Global Health and Physical Functioning subscales). There is a significant difference in change in weight (mean difference [MD]: 1.22, 95% CI: 1.05-1.38, < .01) and HRQoL scores (Global Health [MD: 14.40, 95% CI: 9.22-19.59, < .01] and Physical Functioning [MD: 10.38, 95% CI: 8.50-12.27, < .01] subscales) favoring the omega-3 fatty acids group. The change in lean body/skeletal mass is not significant (MD: 2.05, 95% CI: -0.55 to 4.66, = .12).

Conclusions: Among patients with advanced non-small cell lung cancer and cancer cachexia, supplementation with omega-3 fatty acids leads to a significant increase in weight and HRQoL scores but not in change in lean body/skeletal mass.

References

van der Meij B, Langius J, Smit E, Spreeuwenberg M, von Blomberg B, Heijboer A . Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr. 2010; 140(10):1774-80. DOI: 10.3945/jn.110.121202. View

Fearon K, Barber M, Moses A, Ahmedzai S, Taylor G, Tisdale M . Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006; 24(21):3401-7. DOI: 10.1200/JCO.2005.04.5724. View

Delpino F, Figueiredo L . Effects of omega-3 supplementation on lean body mass in cancer patients: a systematic review and meta-analysis. Eur J Clin Nutr. 2022; 76(12):1636-1645. DOI: 10.1038/s41430-022-01100-x. View

Wigmore S, Barber M, Ross J, Tisdale M, Fearon K . Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000; 36(2):177-84. DOI: 10.1207/S15327914NC3602_6. View

Barber M, Ross J, Voss A, Tisdale M, Fearon K . The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999; 81(1):80-6. PMC: 2374349. DOI: 10.1038/sj.bjc.6690654. View

Sanchez-Lara K, Turcott J, Juarez-Hernandez E, Nunez-Valencia C, Villanueva G, Guevara P . Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014; 33(6):1017-23. DOI: 10.1016/j.clnu.2014.03.006. View

Evans W, Makuch R, Clamon G, Feld R, WEINER R, Moran E . Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 1985; 45(7):3347-53. View

Beck S, Smith K, Tisdale M . Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991; 51(22):6089-93. View

Tisdale M . Biology of cachexia. J Natl Cancer Inst. 1997; 89(23):1763-73. DOI: 10.1093/jnci/89.23.1763. View

10.

Ovesen L, Allingstrup L, Hannibal J, Mortensen E, Hansen O . Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993; 11(10):2043-9. DOI: 10.1200/JCO.1993.11.10.2043. View

11.

Dewey A, Baughan C, Dean T, Higgins B, Johnson I . Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007; (1):CD004597. PMC: 6464930. DOI: 10.1002/14651858.CD004597.pub2. View

12.

Murphy R, Mourtzakis M, Chu Q, Baracos V, Reiman T, Mazurak V . Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011; 117(8):1775-82. DOI: 10.1002/cncr.25709. View

13.

Willox J, Corr J, Shaw J, Richardson M, Calman K, Drennan M . Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed). 1984; 288(6410):27. PMC: 1444189. DOI: 10.1136/bmj.288.6410.27. View

14.

van der Meij B, Langius J, Spreeuwenberg M, Slootmaker S, Paul M, Smit E . Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr. 2012; 66(3):399-404. PMC: 3303137. DOI: 10.1038/ejcn.2011.214. View

15.

Downer S, Joel S, Allbright A, Plant H, Stubbs L, Talbot D . A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer. 1993; 67(5):1102-5. PMC: 1968469. DOI: 10.1038/bjc.1993.202. View

16.

Fearon K, Von Meyenfeldt M, Moses A, Van Geenen R, Roy A, Gouma D . Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003; 52(10):1479-86. PMC: 1773823. DOI: 10.1136/gut.52.10.1479. View

17.

Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M . Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. 2011; 108(2):327-33. DOI: 10.1017/S0007114511005551. View

18.

Gogos C, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos N, Kalfarentzos F . Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998; 82(2):395-402. DOI: 10.1002/(sici)1097-0142(19980115)82:2<403::aid-cncr21>3.0.co;2-1. View